Timi score Calculator for Uanstemi

Calculate timiscore uanstemi quickly with our cardiovascular system tool. Get results based on evidence-based formulas with clear explanations.

Share this calculator

X Facebook LinkedIn

Formula

TIMI Score = Sum of 7 binary risk factors (0-7 points)

Each of seven factors adds one point: age >= 65, >= 3 CAD risk factors, known CAD with >= 50% stenosis, aspirin use in past 7 days, >= 2 anginal episodes in 24 hours, ST deviation >= 0.5mm, and elevated cardiac markers. Higher scores indicate greater 14-day event risk.

Worked Examples

Example 1: Low-Risk UA/NSTEMI Assessment

Problem: A 52-year-old patient presents with chest pain, has 1 CAD risk factor (smoking), no known CAD, not on aspirin, single episode of angina, no ST changes, and normal troponin.

Solution: TIMI Score calculation:\nAge >= 65: No (0 points)\nCAD risk factors >= 3: No, only 1 (0 points)\nKnown CAD >= 50% stenosis: No (0 points)\nAspirin use past 7 days: No (0 points)\nSevere angina >= 2 episodes/24h: No (0 points)\nST deviation >= 0.5mm: No (0 points)\nElevated cardiac markers: No (0 points)\nTotal TIMI Score = 0

Result: TIMI Score: 0/7 | Low Risk | 14-day event rate: 4.7% | Conservative management appropriate

Example 2: High-Risk UA/NSTEMI Assessment

Problem: A 70-year-old patient on aspirin with hypertension, diabetes, smoking, and hypercholesterolemia (4 risk factors). Known prior coronary stenting. Had 3 angina episodes in past 24 hours with 1mm ST depression and elevated troponin.

Solution: TIMI Score calculation:\nAge >= 65: Yes (+1 point)\nCAD risk factors >= 3: Yes, 4 factors (+1 point)\nKnown CAD >= 50% stenosis: Yes, prior stenting (+1 point)\nAspirin use past 7 days: Yes (+1 point)\nSevere angina >= 2 episodes/24h: Yes, 3 episodes (+1 point)\nST deviation >= 0.5mm: Yes, 1mm depression (+1 point)\nElevated cardiac markers: Yes, troponin elevated (+1 point)\nTotal TIMI Score = 7

Result: TIMI Score: 7/7 | High Risk | 14-day event rate: 40.9% | Urgent invasive strategy recommended

Frequently Asked Questions

What is the TIMI Risk Score for UA/NSTEMI and what does it predict?

The TIMI (Thrombolysis In Myocardial Infarction) Risk Score for UA/NSTEMI is a validated clinical tool that predicts the risk of death, myocardial infarction, or urgent revascularization within 14 days of presentation in patients with unstable angina or non-ST elevation myocardial infarction. Developed by Antman and colleagues in 2000, the score uses seven easily assessed clinical variables, each worth one point, creating a simple 0 to 7 scale. The score was derived from the TIMI 11B trial and validated in multiple subsequent studies and registries. Its primary clinical utility is in guiding the decision between conservative medical management and an early invasive strategy with cardiac catheterization. Higher scores indicate greater benefit from early invasive management with dual antiplatelet therapy and anticoagulation.

What are the seven variables in the TIMI Risk Score for UA/NSTEMI?

The seven variables in the TIMI Risk Score for UA/NSTEMI are each scored as present (1 point) or absent (0 points). First, age 65 years or older. Second, having at least three coronary artery disease risk factors, which include family history of coronary artery disease, hypertension, hypercholesterolemia, diabetes, and current smoking. Third, known coronary artery disease defined as prior coronary stenosis of 50 percent or greater documented by catheterization. Fourth, aspirin use within the past seven days, which paradoxically indicates higher risk because it suggests aspirin-refractory disease. Fifth, at least two episodes of severe anginal pain within the past 24 hours. Sixth, ST-segment deviation of 0.5 millimeters or more on the presenting electrocardiogram. Seventh, elevated serum cardiac biomarkers such as troponin or CK-MB.

How does the TIMI score guide treatment decisions in acute coronary syndromes?

The TIMI score directly influences the choice between conservative and invasive management strategies in UA/NSTEMI patients. Patients with low scores (0 to 2) have a 14-day event rate under 8.3 percent and may be managed conservatively with medical therapy and non-invasive stress testing for risk stratification. Intermediate-risk patients (scores 3 to 4) have event rates of 13 to 20 percent and generally benefit from an early invasive strategy with cardiac catheterization within 24 to 72 hours. High-risk patients (scores 5 to 7) have event rates exceeding 26 percent and should receive urgent invasive evaluation within 24 hours along with intensive antiplatelet therapy including glycoprotein IIb/IIIa inhibitors or P2Y12 inhibitors. Current ACC/AHA guidelines incorporate the TIMI score as one factor in determining the timing and aggressiveness of intervention.

Why does aspirin use in the past week increase the TIMI risk score?

The inclusion of recent aspirin use as a risk-increasing variable may seem counterintuitive since aspirin is a cornerstone of acute coronary syndrome treatment. However, patients who are already taking aspirin and still develop UA/NSTEMI have demonstrated aspirin-refractory disease, meaning their atherothrombotic process has overcome the antiplatelet effect of aspirin. This indicates more aggressive underlying pathology and a higher likelihood of adverse outcomes. These patients often have more extensive coronary artery disease, more active plaque biology, and greater thrombotic potential. The aspirin criterion also serves as a marker for patients with known cardiovascular disease who are already on preventive therapy, suggesting established vascular disease burden. Studies have confirmed that this variable independently predicts worse outcomes even after adjusting for other risk factors.

How does the TIMI score for UA/NSTEMI differ from the TIMI score for STEMI?

The TIMI scores for UA/NSTEMI and STEMI are completely different scoring systems designed for different clinical scenarios. The UA/NSTEMI version uses seven dichotomous variables (present or absent) to predict 14-day events including death, MI, and need for revascularization, with scores ranging from 0 to 7. The STEMI version uses different variables including age ranges, vital signs, Killip class, body weight, anterior ST elevation, time to treatment, and diabetes/hypertension/angina history. It predicts 30-day mortality specifically, with scores ranging from 0 to 14. The two scores should never be interchanged because they apply to fundamentally different clinical presentations. UA/NSTEMI involves partial coronary occlusion with subendocardial ischemia, while STEMI involves complete coronary occlusion requiring emergent reperfusion therapy.

What are the limitations of the TIMI Risk Score in clinical practice?

The TIMI Risk Score has several recognized limitations despite its widespread use and validation. The score uses equal weighting for all seven variables, which may not reflect their true relative importance. Some clinicians argue that troponin elevation and ST changes should carry more weight than age alone. The score does not account for renal function, which is a powerful predictor of outcomes in acute coronary syndromes. It also does not incorporate newer biomarkers such as BNP or NT-proBNP that have proven prognostic value. The original validation cohorts may not fully represent current patient demographics, and treatment advances since 2000 have improved outcomes across all risk categories. Additionally, the score provides population-level risk estimates rather than individual patient predictions, and clinical judgment should always complement any scoring system.